AnaptysBio (NASDAQ:ANAB) Given New $66.00 Price Target at JPMorgan Chase & Co.

AnaptysBio (NASDAQ:ANAB) had its price objective dropped by research analysts at JPMorgan Chase & Co. from $75.00 to $66.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 218.07% from the company’s current price.

Several other research analysts also recently weighed in on the company. UBS Group upped their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Wedbush restated an “outperform” rating and issued a $42.00 price target on shares of AnaptysBio in a research note on Wednesday, November 6th. Guggenheim upped their price target on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. HC Wainwright dropped their price target on AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Truist Financial increased their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.64.

AnaptysBio Trading Down 3.5 %

AnaptysBio stock opened at $20.75 on Tuesday. The firm has a 50 day moving average of $32.06 and a 200 day moving average of $30.02. The firm has a market capitalization of $631.42 million, a price-to-earnings ratio of -3.45 and a beta of -0.24. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, analysts predict that AnaptysBio will post -6.09 EPS for the current year.

Insider Activity at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the sale, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,440 shares of company stock worth $892,936. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio in the first quarter worth $38,000. Values First Advisors Inc. purchased a new stake in AnaptysBio in the third quarter worth $49,000. nVerses Capital LLC increased its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the period. Headlands Technologies LLC increased its stake in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.